Acorda Therapeutics has entered into an agreement with Chance Pharmaceuticals for Inbrija (levodopa inhalation powder), a medication…
Articles by Margarida Maia, PhD
A once-daily 200 mg dose of IkT-148009, Inhibikase Therapeutics‘ investigational therapy for Parkinson’s disease, reached steady levels in…
The U.S. Food and Drug Administration (FDA) has requested more information about the specialized pump used to administer ABBV-951…
IMAC Holdings and Brain Scientific have agreed to merge to offer solutions that cover the spectrum of care…
People with idiopathic Parkinson’s disease have significantly higher blood levels of neurofilament light chain (NfL) — a biomarker of nerve…
Microglia, the brain’s resident immune cells, may contribute to Parkinson’s disease by releasing tiny vesicles filled with alpha-synuclein —…
Among several atypical antipsychotics, Nuplazid (pimavanserin) seems to be the most effective at easing Parkinson’s disease psychosis (PDP)…
People with REM sleep behavior disorder (RBD), a sleep disturbance that can precede Parkinson’s disease, have higher levels of toxic…
Microglia — the brain’s primary immune cells — can help to keep motor symptoms of Parkinson’s disease from quickly…
Subthalamic deep brain stimulation (DBS) may bring benefits to people with Parkinson’s regardless of whether the disease is…